By Colin Kellaher

 

Arrowhead Pharmaceuticals Inc. (ARWR) on Wednesday said it earned a $25 million milestone payment after a unit of Johnson & Johnson (JNJ) began a phase 2b combination study in patients with chronic hepatitis B infection.

The Pasadena, Calif., drug developer said J&J's Janssen Pharmaceuticals unit has begun dosing in the study of different combination regimens, including JNJ-3989, formerly ARO-HBV.

Arrowhead in October agreed to work with Janssen to develop and commercialize ARO-HBV as part of a license and collaboration agreement potentially worth more than $3.7 billion to Arrowhead.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 28, 2019 09:07 ET (13:07 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Arrowhead Pharmaceuticals Charts.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Arrowhead Pharmaceuticals Charts.